- Home
- STEC vs IGC Comparison
STEC vs IGC Comparison
Compare STEC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- IGC
- Stock Information
- Founded
- STEC 2006
- IGC 2005
- Country
- STEC China
- IGC United States
- Employees
- STEC N/A
- IGC N/A
- Industry
- STEC
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- IGC Health Care
- Exchange
- STEC NYSE
- IGC Nasdaq
- Market Cap
- STEC 19.0M
- IGC 19.1M
- IPO Year
- STEC 2021
- IGC N/A
- Fundamental
- Price
- STEC $1.33
- IGC $0.28
- Analyst Decision
- STEC
- IGC Strong Buy
- Analyst Count
- STEC 0
- IGC 2
- Target Price
- STEC N/A
- IGC $3.88
- AVG Volume (30 Days)
- STEC 42.5K
- IGC 415.4K
- Earning Date
- STEC 04-08-2025
- IGC 02-18-2025
- Dividend Yield
- STEC N/A
- IGC N/A
- EPS Growth
- STEC N/A
- IGC N/A
- EPS
- STEC N/A
- IGC N/A
- Revenue
- STEC $260,474,693.00
- IGC $1,236,000.00
- Revenue This Year
- STEC $9.76
- IGC N/A
- Revenue Next Year
- STEC $15.85
- IGC $18.34
- P/E Ratio
- STEC N/A
- IGC N/A
- Revenue Growth
- STEC N/A
- IGC 1.65
- 52 Week Low
- STEC $0.20
- IGC $0.26
- 52 Week High
- STEC $3.25
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- STEC 45.61
- IGC 40.22
- Support Level
- STEC $1.21
- IGC $0.29
- Resistance Level
- STEC $1.35
- IGC $0.32
- Average True Range (ATR)
- STEC 0.11
- IGC 0.02
- MACD
- STEC -0.04
- IGC -0.00
- Stochastic Oscillator
- STEC 12.12
- IGC 2.50
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.